Fifth Third Wealth Advisors LLC Has $1.40 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Fifth Third Wealth Advisors LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 14.7% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 8,521 shares of the company’s stock after acquiring an additional 1,095 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Zoetis were worth $1,403,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. New Hampshire Trust grew its stake in Zoetis by 6.4% in the first quarter. New Hampshire Trust now owns 10,356 shares of the company’s stock valued at $1,705,000 after acquiring an additional 619 shares during the period. Fulcrum Capital LLC lifted its holdings in shares of Zoetis by 3.4% in the first quarter. Fulcrum Capital LLC now owns 52,546 shares of the company’s stock valued at $8,652,000 after purchasing an additional 1,728 shares in the last quarter. Lantz Financial LLC lifted its holdings in shares of Zoetis by 79.7% in the first quarter. Lantz Financial LLC now owns 2,221 shares of the company’s stock valued at $366,000 after purchasing an additional 985 shares in the last quarter. GoalVest Advisory LLC lifted its holdings in shares of Zoetis by 64.8% in the first quarter. GoalVest Advisory LLC now owns 440 shares of the company’s stock valued at $72,000 after purchasing an additional 173 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Zoetis by 14,731.3% in the first quarter. GAMMA Investing LLC now owns 1,759,285 shares of the company’s stock valued at $289,666,000 after purchasing an additional 1,747,423 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. UBS Group dropped their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $212.75.

Zoetis Stock Performance

Shares of Zoetis stock opened at $168.71 on Monday. The business’s fifty day simple moving average is $156.80 and its 200 day simple moving average is $164.43. The firm has a market capitalization of $75.11 billion, a P/E ratio of 30.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $1.38 earnings per share. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis’s payout ratio is presently 35.91%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.